| Outcome |
Findings in words |
Findings in numbers |
Quality of evidence |
| Global state |
Clinical improvement
Follow-up: average 19 weeks | Trifluoperazine increases the chance of being 'improved' when compared to placebo. Data are based on low quality evidence.
| RR 4.61 (1.54 to 13.84) | Low |
|
Relapse or worsening
Follow-up: average 5 months | Trifluoperazine reduces the risk of relapse when compared with placebo. Data are based on low quality evidence.
| RR 0.34 (0.23 to 0.49) | Low |
| Mental state |
Experiencing 'intensified symptoms'
Follow-up: average 16 weeks | At present it is not possible to be confident about the difference between trifluoperazine and placebo for this outcome and data supporting this finding are very limited.
| RR 1.05 (0.54 to 2.05) | Very low |
| Leaving the study early |
- Because of any reason
Follow-up: average 5 months | Trifluoperazine may reduce loss to follow-up, but, at present it is not possible to be confident about the difference between the two treatments and data supporting this finding are very limited.
| RR 0.67 (0.38 to 1.19) | Very low |
- Because of severe adverse effects
Follow-up: average 2 months | It is not possible to be confident about the difference between trifluoperazine and placebo. Data supporting this finding are very limited.
| RR 1.31 (0.22 to 7.8) | Very low |
| Behavior |
Any clinically significant agitation or distress
Follow-up: 4 months | There was no clear differences between trifluoperazine and placebo for this outcome. Data supporting this finding are very limited.
| RR 2.0 (0.19 to 20.72) | Very low |
| Economic outcomes |
| No included randomized study reported on economic outcomes. | | |
|
